“慢性诱发性荨麻疹是一种毁灭性疾病，尽管患者时刻保持警惕，但他们往往无法避免疾病诱因，并受到严重瘙痒和灼热荨麻疹的影响，”首席医疗官 Diane C． Young 在声明中表示。Biopharmaceutical company Celldex Therapeutics announced that in the chronic inducible urticaria study, Barzolvolimab achieved all primary and secondary endpoints with high statistical significance.
Barzolvolimab (CDX 0159) is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specifically and effectively inhibits the activation of KIT. Barzolvolimab can reduce skin mast cell hypertrophy and disease activity in chronic inducible urticaria.
According to a statement, the focus of the second phase of the study is on the two most common types of chronic inducible urticaria.
"Chronic inducible urticaria is a devastating disease, despite patients being vigilant at all times, they often cannot avoid disease triggers and suffer from severe itching and burning hives," Chief Medical Officer Diane C. Young stated in a declaration.
The company will hold a live webcast conference call on Monday morning at 8:00 AM Eastern Time.
